NAPEPLD
ENSG00000161048
Target class
Enzyme
Chromosome
7
- Chemical probe available
- No
- Target name
- NAPEPLD
- Gene name
- N-acyl phosphatidylethanolamine phospholipase D
- Gene symbol
- NAPEPLD
- Protein name
- N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (N-acyl phosphatidylethanolamine phospholipase D) (NAPE-PLD) (NAPE-hydrolyzing phospholipase D) (EC 3.1.4.54)
- FMP30
- C7orf18
- NAPE-PLD
- Gene biotype
- Protein coding
- Gene family
- Metallo-beta-lactamase fold containing family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 32.1
- Tissue specificity (Gini)
- 0.285
- Tissue specificity (tau)
- 0.701
- KEGG gene identifiers
- hsa:222236
- Reactome pathways
- R-HSA-2466712
- Protein interaction confidence
- 0.8485
- Protein interaction partners
- 14
- End position
- 103151172
- Start position
- 103099776
- Chromosome
- 7
- Strand
- Reverse
- Golgi apparatus membrane
- Peripheral membrane protein . Early endosome membrane
- Peripheral membrane protein . Nucleus envelope . Nucleus, nucleoplasm . Note=Localized in the proximity of the cellular membranes likely through interaction with membrane phospholipids. .
Publication evidence
- PubMed 25684574
- Tissue specificity (tau)
- 0.700688
- Expression inequality (Gini)
- 0.284656
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 32.1
- Brain - Cerebellum
- 27.02
- Testis
- 20.19
- Ovary
- 19.08
- Brain - Frontal Cortex (BA9)
- 18.85
Expression in transcripts per million
- Brain - Cerebellar Hemisphere32.1
- Brain - Cerebellum27.02
- Testis20.19
- Ovary19.08
- Brain - Frontal Cortex (BA9)18.85
- Nerve - Tibial16.71
- Thyroid16.68
- Spleen14.39
- Brain - Spinal cord (cervical c-1)14.36
- Brain - Cortex13.98
- Artery - Aorta13.23
- Cervix - Endocervix12.24
- Cervix - Ectocervix11.94
- Colon - Transverse11.51
- Small Intestine - Terminal Ileum11.13
- Artery - Tibial10.95
- Uterus10.78
- Brain - Anterior cingulate cortex (BA24)10.45
- Artery - Coronary10.29
- Kidney - Medulla10.19
- Brain - Caudate (basal ganglia)9.88
- Brain - Hippocampus9.82
- Prostate9.6
- Pituitary9.45
- Brain - Substantia nigra9.16
And 29 more, listed on the interactive page.
Biological processes
- GO:0070292
- GO:0000139
- GO:0005635
- GO:0005794
- GO:0031901
- GO:0042622
- GO:0070062
- GO:0008270
- GO:0032052
- GO:0042802
- GO:0070290
Related records
Trials (430)
- 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
- 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
- A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
- A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
- A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide
- A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM
- A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
- A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
- A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide
- A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
- A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein
- A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
- A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD
- A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
- A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections
- A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
- A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension
- A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
- A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
Drugs (5)
- Bithionol
- Chlorthalidone
- Hexachlorophene
- Hydrochlorothiazide
- Indapamide